Amgen. Amgen, Cytokinetics and Servier announce topline results from GALACTIC-HF, a phase 3 trial of omecamtiv mecarbil In patients with heart failure. News release. October 8, 2020. Accessed October 15, 2020. http://investors.amgen.com/news-releases/news-release-details/amgen-cytokinetics-and-servier-announce-topline-results-galactic
Teerlink JR. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: the global approach to lowering adverse cardiac outcomes through improving contractility in heart failure (GALACTIC-HF) trial. American Heart Association. Accessed October 15, 2020. https://www.abstractsonline.com/pp8/?&_ga=2.205885075.1446428122.1602780183-845841488.1602780183#!/9144/session/828
Arrigo M, Nijst P, Rudiger A. Optimising heart failure therapies in the acute setting. Card Fail Rev. 2018;4:38-42.
Bilkey GA, Burns BL, Coles EP, et al. Optimizing precision medicine for public health. Front Public Health. 2019;7:42.
Butler J, Kalogeropoulos A. Worsening heart failure hospitalization epidemic we do not know how to prevent and we do not know how to treat. J Am Coll Cardiol. 2008;52:435-437.
Chun S, Tu JV, Wijeysundera HC, et al Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure. Circ Heart Fail. 2012;5:414-421.
Gattis WA, O’Connor CM, Gallup DS, et al; IMPACT-HF Investigators and Coordinators. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol. 2004;43:1534-1541.
Greene SJ, Fonarow GC, Vaduganathan M, et al. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol. 2015;12:220-229.
Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012;21:365-371.
Krumholz HM, Merrill AR, Schone EM, et al. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes. 2009;2:407-413.
Liu Y, White HD, Belknap B, et al. Omecamtiv mecarbil modulates the kinetic and motile properties of porcine β-cardiac myosin. Biochemistry. 2015;54:1963-1975.
Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011;331:1439-1443.
Marti CN, Fonarow GC, Gheorghiade M, et al. Timing and duration of interventions in clinical trials for patients with hospitalized heart failure. Circ Heart Fail. 2013;6:1095-1101.
McMurray JJV, Packer M, Desai AS, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008.
Morrow DA, Velazquez EJ, DeVore AD, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial. Circulation. 2019;139:2285-2288.
Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;838:1413-1424.
Pascual-Figal D, Wachter R, Senni M, et al. Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan. ESC Heart Fail. 2018;5:327-336.
Pharmacy Times. Switching HF medications in the inpatient setting. 2017. https://www.pharmacytimes.com/peer-exchange/heart-failure/switching-hf-medications-in-the-inpatient-setting.
Ponikowski P, Voors AA, Anker SD, et al; ESC Scientific Document Group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200.
Psotka MA, Gottlieb SS, Francis GS, et al. Cardiac calcitropes, myotropes, and mitotropes: JACC review topic of the week. J Am Coll Cardiol. 2019;73:2345-2353.
Ross JS, Chen J, Lin Z, et al. Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail. 2010;3:97-103.
Sabbah HN. Silent disease progression in clinically stable heart failure. Eur J Heart Fail. 2017;19:469-478.
Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:1169-1186.
Solomon SD, Dobson J, Pocock S, et al; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116:1482-1487.
Teerlink JR, Diaz R, Felker GM, et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC Heart Fail. 2020;8:329-340.
Teerlink JR, Diaz R, Felker GM, et al; GALACTIC-HF Investigators. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC-HF: baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail. 2020. doi:10.1002/ejhf.2015 [Epub ahead of print]
Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396:121-128.
Velazquez EJ, Morrow DA, DeVore AD, et al; PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380:539-548.
von Lueder TG, Kotecha D, Atar D, et al. Neurohormonal blockade in heart failure. Card Fail Rev. 2017;3:19-24.
Wachter R, Senni M, Belohlavek J, et al; TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019;21:998-1007.
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137-e161.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Moderator

Stefan D. Anker, MD, PhD

Professor
Department of Cardiology & Metabolism
Berlin-Brandenburg Center for Regenerative Therapies (BCRT)
Charité-Universitätsmedizin
Berlin, Germany

Disclosures

Disclosure: Stefan D. Anker, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott; Bayer; Boehringer Ingelheim; Brahms; Novartis; Vifor

Faculty

Adrian Hernandez, MD, PhD

Vice Dean and Executive Director
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina, United States

Disclosures

Disclosure: Adrian Hernandez, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Merck; Novartis; Relypsa
Received grants for clinical research from: AstraZeneca; Boehringer Ingelheim; Merck; Novartis; Verily

Muthiah Vaduganathan, MD, MPH

Attending Cardiologist
Division of Cardiovascular Medicine
Brigham and Women’s Hospital
Instructor of Medicine
Harvard Medical School
Boston, Massachusetts, United States

Disclosures

Disclosure: Muthiah Vaduganathan, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; AstraZeneca; Baxter Healthcare; Bayer AG; Boehringer Ingelheim; Cytokinetics; Relypsa
Served as a speaker or a member of a speakers bureau for: Novartis
Received grants for clinical research from: Amgen
Other: Clinical Endpoints Committees for Galmed; NIH; Novartis

Editor

Anne M. Sendaydiego, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Anne M. Sendaydiego, PharmD, has disclosed no relevant financial relationships.

Content Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:

CPD

Emerging Treatment Pathways for HFrEF Patients: What Does the Evidence Say?

Authors: Stefan D. Anker, MD, PhD; Adrian Hernandez, MD, PhD; Muthiah Vaduganathan, MD, MPH
CPD Released: 2/24/2021
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 2/24/2022

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US cardiologists, primary care providers, and nephrologists.

The goal of this activity is to review challenges association with the management of patients with heart failure with reduced ejection fraction (HFrEF) and how new agents in clinical development may have a future role in HFrEF treatment.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Challenges associated with the management of patients with HFrEF
- Mechanism of action of emerging agents for the management of patients with HFrEF, including the selective cardiac myosin activators
Have greater competence related to
- Appropriately manage patients with HFrEF in order to minimize cardiovascular-related morbidity and mortality

Disclosures

Moderator

Stefan D. Anker, MD, PhD

Professor
Department of Cardiology & Metabolism
Berlin-Brandenburg Center for Regenerative Therapies (BCRT)
Charité-Universitätsmedizin
Berlin, Germany

Disclosures

Disclosure: Stefan D. Anker, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott; Bayer; Boehringer Ingelheim; Brahms; Novartis; Vifor

Faculty

Adrian Hernandez, MD, PhD

Vice Dean and Executive Director
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina, United States

Disclosures

Disclosure: Adrian Hernandez, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Merck; Novartis; Relypsa
Received grants for clinical research from: AstraZeneca; Boehringer Ingelheim; Merck; Novartis; Verily

Muthiah Vaduganathan, MD, MPH

Attending Cardiologist
Division of Cardiovascular Medicine
Brigham and Women’s Hospital
Instructor of Medicine
Harvard Medical School
Boston, Massachusetts, United States

Disclosures

Disclosure: Muthiah Vaduganathan, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; AstraZeneca; Baxter Healthcare; Bayer AG; Boehringer Ingelheim; Cytokinetics; Relypsa
Served as a speaker or a member of a speakers bureau for: Novartis
Received grants for clinical research from: Amgen
Other: Clinical Endpoints Committees for Galmed; NIH; Novartis

Editor

Anne M. Sendaydiego, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Anne M. Sendaydiego, PharmD, has disclosed no relevant financial relationships.

Content Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Emerging Treatment Pathways for HFrEF Patients: What Does the Evidence Say?

Authors: Stefan D. Anker, MD, PhD; Adrian Hernandez, MD, PhD; Muthiah Vaduganathan, MD, MPHFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CPD Released: 2/24/2021

Valid for credit through: 2/24/2022

processing....

Deutsche Untertitel

« Return to: Emerging Treatment Pathways for HFrEF Patients: What Does the Evidence Say?

Download Slides

Print
Like Tweet

References

Faculty and Disclosures

Moderator

Stefan D. Anker, MD, PhD

Faculty

Adrian Hernandez, MD, PhD

Muthiah Vaduganathan, MD, MPH

Editor

Anne M. Sendaydiego, PharmD

Content Reviewer

Esther Nyarko, PharmD

Peer Reviewer

CPD

Emerging Treatment Pathways for HFrEF Patients: What Does the Evidence Say?

Target Audience and Goal Statement

Disclosures

Moderator

Stefan D. Anker, MD, PhD

Faculty

Adrian Hernandez, MD, PhD

Muthiah Vaduganathan, MD, MPH

Editor

Anne M. Sendaydiego, PharmD

Content Reviewer

Esther Nyarko, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Emerging Treatment Pathways for HFrEF Patients: What Does the Evidence Say?

Deutsche Untertitel